Cargando…

The prognostic impact of programmed cell death ligand 1 and human leukocyte antigen class I in pancreatic cancer

Pancreatic ductal adenocarcinoma (PDA) is associated with an immunosuppressive tumor‐microenvironment (TME) that supports the growth of tumors and mediates tumors enabling evasion of the immune system. Expression of programmed cell death ligand 1 (PD‐L1) and loss of human leukocyte antigen (HLA) cla...

Descripción completa

Detalles Bibliográficos
Autores principales: Imai, Daisuke, Yoshizumi, Tomoharu, Okano, Shinji, Uchiyama, Hideaki, Ikegami, Toru, Harimoto, Norifumi, Itoh, Shinji, Soejima, Yuji, Aishima, Shinichi, Oda, Yoshinao, Maehara, Yoshihiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5504334/
https://www.ncbi.nlm.nih.gov/pubmed/28602029
http://dx.doi.org/10.1002/cam4.1087
_version_ 1783249270409789440
author Imai, Daisuke
Yoshizumi, Tomoharu
Okano, Shinji
Uchiyama, Hideaki
Ikegami, Toru
Harimoto, Norifumi
Itoh, Shinji
Soejima, Yuji
Aishima, Shinichi
Oda, Yoshinao
Maehara, Yoshihiko
author_facet Imai, Daisuke
Yoshizumi, Tomoharu
Okano, Shinji
Uchiyama, Hideaki
Ikegami, Toru
Harimoto, Norifumi
Itoh, Shinji
Soejima, Yuji
Aishima, Shinichi
Oda, Yoshinao
Maehara, Yoshihiko
author_sort Imai, Daisuke
collection PubMed
description Pancreatic ductal adenocarcinoma (PDA) is associated with an immunosuppressive tumor‐microenvironment (TME) that supports the growth of tumors and mediates tumors enabling evasion of the immune system. Expression of programmed cell death ligand 1 (PD‐L1) and loss of human leukocyte antigen (HLA) class I on tumor cells are methods by which tumors escape immunosurveillance. We examined immune cell infiltration, the expression of PD‐L1 and HLA class I by PDA cells, and the correlation between these immunological factors and clinical prognosis. PDA samples from 36 patients were analyzed for HLA class I, HLA‐DR, PD‐L1, PD‐1, CD4, CD8, CD56, CD68, and FoxP3 expression by immunohistochemistry. The correlations between the expression of HLA class I, HLA‐DR, PD‐L1 or PD‐1 and the pattern of tumor infiltrating immune cells or the patients’ prognosis were assessed. PD‐L1 expression correlated with tumor infiltration by CD68(+) and FoxP3(+) cells. Low HLA class I expression was an only risk factor for poor survival. PD‐L1 negative and HLA class I high‐expressing PDA was significantly associated with higher numbers of infiltrating CD8(+) T cells in the TME, and a better prognosis. Evaluation of both PD‐L1 and HLA class I expression by PDA may be a good predictor of prognosis for patients. HLA class I expression by tumor cells should be evaluated when selecting PDA patients who may be eligible for treatment with PD‐1/PD‐L1 immune checkpoint blockade therapies.
format Online
Article
Text
id pubmed-5504334
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-55043342017-07-12 The prognostic impact of programmed cell death ligand 1 and human leukocyte antigen class I in pancreatic cancer Imai, Daisuke Yoshizumi, Tomoharu Okano, Shinji Uchiyama, Hideaki Ikegami, Toru Harimoto, Norifumi Itoh, Shinji Soejima, Yuji Aishima, Shinichi Oda, Yoshinao Maehara, Yoshihiko Cancer Med Clinical Cancer Research Pancreatic ductal adenocarcinoma (PDA) is associated with an immunosuppressive tumor‐microenvironment (TME) that supports the growth of tumors and mediates tumors enabling evasion of the immune system. Expression of programmed cell death ligand 1 (PD‐L1) and loss of human leukocyte antigen (HLA) class I on tumor cells are methods by which tumors escape immunosurveillance. We examined immune cell infiltration, the expression of PD‐L1 and HLA class I by PDA cells, and the correlation between these immunological factors and clinical prognosis. PDA samples from 36 patients were analyzed for HLA class I, HLA‐DR, PD‐L1, PD‐1, CD4, CD8, CD56, CD68, and FoxP3 expression by immunohistochemistry. The correlations between the expression of HLA class I, HLA‐DR, PD‐L1 or PD‐1 and the pattern of tumor infiltrating immune cells or the patients’ prognosis were assessed. PD‐L1 expression correlated with tumor infiltration by CD68(+) and FoxP3(+) cells. Low HLA class I expression was an only risk factor for poor survival. PD‐L1 negative and HLA class I high‐expressing PDA was significantly associated with higher numbers of infiltrating CD8(+) T cells in the TME, and a better prognosis. Evaluation of both PD‐L1 and HLA class I expression by PDA may be a good predictor of prognosis for patients. HLA class I expression by tumor cells should be evaluated when selecting PDA patients who may be eligible for treatment with PD‐1/PD‐L1 immune checkpoint blockade therapies. John Wiley and Sons Inc. 2017-06-10 /pmc/articles/PMC5504334/ /pubmed/28602029 http://dx.doi.org/10.1002/cam4.1087 Text en © 2017 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution (http://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Clinical Cancer Research
Imai, Daisuke
Yoshizumi, Tomoharu
Okano, Shinji
Uchiyama, Hideaki
Ikegami, Toru
Harimoto, Norifumi
Itoh, Shinji
Soejima, Yuji
Aishima, Shinichi
Oda, Yoshinao
Maehara, Yoshihiko
The prognostic impact of programmed cell death ligand 1 and human leukocyte antigen class I in pancreatic cancer
title The prognostic impact of programmed cell death ligand 1 and human leukocyte antigen class I in pancreatic cancer
title_full The prognostic impact of programmed cell death ligand 1 and human leukocyte antigen class I in pancreatic cancer
title_fullStr The prognostic impact of programmed cell death ligand 1 and human leukocyte antigen class I in pancreatic cancer
title_full_unstemmed The prognostic impact of programmed cell death ligand 1 and human leukocyte antigen class I in pancreatic cancer
title_short The prognostic impact of programmed cell death ligand 1 and human leukocyte antigen class I in pancreatic cancer
title_sort prognostic impact of programmed cell death ligand 1 and human leukocyte antigen class i in pancreatic cancer
topic Clinical Cancer Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5504334/
https://www.ncbi.nlm.nih.gov/pubmed/28602029
http://dx.doi.org/10.1002/cam4.1087
work_keys_str_mv AT imaidaisuke theprognosticimpactofprogrammedcelldeathligand1andhumanleukocyteantigenclassiinpancreaticcancer
AT yoshizumitomoharu theprognosticimpactofprogrammedcelldeathligand1andhumanleukocyteantigenclassiinpancreaticcancer
AT okanoshinji theprognosticimpactofprogrammedcelldeathligand1andhumanleukocyteantigenclassiinpancreaticcancer
AT uchiyamahideaki theprognosticimpactofprogrammedcelldeathligand1andhumanleukocyteantigenclassiinpancreaticcancer
AT ikegamitoru theprognosticimpactofprogrammedcelldeathligand1andhumanleukocyteantigenclassiinpancreaticcancer
AT harimotonorifumi theprognosticimpactofprogrammedcelldeathligand1andhumanleukocyteantigenclassiinpancreaticcancer
AT itohshinji theprognosticimpactofprogrammedcelldeathligand1andhumanleukocyteantigenclassiinpancreaticcancer
AT soejimayuji theprognosticimpactofprogrammedcelldeathligand1andhumanleukocyteantigenclassiinpancreaticcancer
AT aishimashinichi theprognosticimpactofprogrammedcelldeathligand1andhumanleukocyteantigenclassiinpancreaticcancer
AT odayoshinao theprognosticimpactofprogrammedcelldeathligand1andhumanleukocyteantigenclassiinpancreaticcancer
AT maeharayoshihiko theprognosticimpactofprogrammedcelldeathligand1andhumanleukocyteantigenclassiinpancreaticcancer
AT imaidaisuke prognosticimpactofprogrammedcelldeathligand1andhumanleukocyteantigenclassiinpancreaticcancer
AT yoshizumitomoharu prognosticimpactofprogrammedcelldeathligand1andhumanleukocyteantigenclassiinpancreaticcancer
AT okanoshinji prognosticimpactofprogrammedcelldeathligand1andhumanleukocyteantigenclassiinpancreaticcancer
AT uchiyamahideaki prognosticimpactofprogrammedcelldeathligand1andhumanleukocyteantigenclassiinpancreaticcancer
AT ikegamitoru prognosticimpactofprogrammedcelldeathligand1andhumanleukocyteantigenclassiinpancreaticcancer
AT harimotonorifumi prognosticimpactofprogrammedcelldeathligand1andhumanleukocyteantigenclassiinpancreaticcancer
AT itohshinji prognosticimpactofprogrammedcelldeathligand1andhumanleukocyteantigenclassiinpancreaticcancer
AT soejimayuji prognosticimpactofprogrammedcelldeathligand1andhumanleukocyteantigenclassiinpancreaticcancer
AT aishimashinichi prognosticimpactofprogrammedcelldeathligand1andhumanleukocyteantigenclassiinpancreaticcancer
AT odayoshinao prognosticimpactofprogrammedcelldeathligand1andhumanleukocyteantigenclassiinpancreaticcancer
AT maeharayoshihiko prognosticimpactofprogrammedcelldeathligand1andhumanleukocyteantigenclassiinpancreaticcancer